Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat in Combination With Darolutamide in mCRPC
NCT07244341Phase 1Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of valemetostat in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-Limiting Toxicities and Treatment Emergent Adverse Events. Started Dec 2025; status: recruiting.
02
Drugs
valemetostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07244341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07244341.